Search

New WHO-Endorsed Test Targets Drug-Resistant TB

By Gift Briton

Known as Xpert MTB/RIF Ultra, the test offers hope for faster and more accurate diagnosis and is anticipated to play a transformative role in global efforts to eradicate TB. The WHO states that the product is ready for government and United Nations agencies to purchase.

“High-quality diagnostic tests are the cornerstone of effective TB care and prevention. Prequalification paves the way for equitable access to cutting-edge technologies, empowering countries to address the dual burden of TB and drug-resistant TB,” said Dr Rogerio Gaspar, WHO Director for Regulation and Prequalification.

Xpert MTB/RIF Ultra can provide accurate results within hours and simultaneously detects genetic mutations linked to drug resistance. This technology will enable doctors to quickly identify resistance to first-line drugs like rifampicin and offer patients alternative treatment.

WHO specifies that the test is intended for patients who screen positive for pulmonary TB and have either not started anti-tuberculosis treatment or received less than three days of therapy in the past six months.

TB is one of the world’s leading infectious disease killers, causing over a million deaths annually. The preventable disease is a chronic burden for sufferers who live mainly in low and middle-income countries. According to WHO, accurate and early detection of TB, especially drug-resistant strains, remains a critical and challenging global health priority.

“This first prequalification of a diagnostic test for tuberculosis marks a critical milestone. It underscores the importance of such groundbreaking diagnostic tools in addressing one of the world’s deadliest infectious diseases,” said Dr Yukiko Nakatani, WHO Assistant Director-General for Access to Medicines and Health Products.

Previous Post
Newer Post

Leave A Comment